Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Merck & Co. Strengthening Its Strong Position In Immuno-Oncology

Digital illustration of Cancer cell in colour background

Related Content

Kalydeco Expands Indication Without Clinical Data; Keytruda Is Latest Bladder Cancer Approval

May 21 2017

Death Excess Gives Pause To Merck & Co Keytruda MM Phase III Studies

Jun 13 2017

Merck's Keytruda Offers Hope And Risk In Early Breast Cancer

Jun 06 2017

Scrip's Rough Guide To IDO

May 18 2017

Keytruda/Chemo Combo Approval Means Merck Holds Crown, For Now

May 11 2017

Bladder Cancer Market Wide Open As Tecentriq Fails Confirmatory 2L Trial

May 10 2017

Could Tecentriq's Bladder Cancer Setback Be A Class Effect?

May 12 2017

Related Companies

Merck & Co., Inc.

Bristol Myers Squibb Company

Roche Holding AG

Eli Lilly and Company

Incyte Corporation

AstraZeneca PLC

Merck KGaA

Pfizer Inc.

Bristol Myers Squibb Company

Additional Topics

ImmunoOncology Clinical Trials Commercial Companies Research & Development Strategy Cancer BioPharmaceutical

More from Immuno-oncology

More from Anticancer

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window